EMHANCE

EMHANCE operates at the intersection of neurotechnology, medical devices, and digital therapeutics. Its proposed differentiation is a portable, non-invasive neuromodulation system that combines targeted low-frequency pulsed electromagnetic stimulation with real-time sensing and AI-driven closed-loop adjustment. That approach places the company conceptually alongside neuromodulation and brain-computer-interface businesses such as Neuronetics, Nevro, Sooma Medical, and Magnus Medical, although the companies address different indications, modalities, and stages of commercialization. Compared with implantable neuromodulation providers such as Nevro, EMHANCE emphasizes a non-invasive format and the possibility of structured, potentially home-capable sessions under clinical supervision. Compared with software-first digital therapeutics, it is pursuing an integrated hardware-and-software platform with physiological feedback and remote oversight. The main competitive constraint is maturity: EMHANCE reports TRL 5 and has not publicly documented regulatory clearance, clinical commercialization, or a disclosed commercial customer base. Its current position is therefore that of an early-stage clinical technology developer rather than an established device vendor.

EMHANCE’s trajectory reflects a transition from research support toward validation of an integrated medical-device platform. The company received a €65,000 R&D grant in 2019, followed by an undisclosed pre-seed round in 2023 Q3 and a €75,000 Women TechEU grant on Oct 24, 2025. Converted at an indicative rate of €1 = $1.08, these disclosed grants represent approximately $151,200 in cumulative funding, excluding the unpriced pre-seed round. The company was formally founded in 2023, when Jasmina Isakovic became CEO and Filip Slatkovic took responsibility for technology, quality, and usability. Product development has progressed to TRL 5, with cell-culture testing completed. The next stated technical inflection point is animal testing, which will be important for assessing safety, repeatability, and therapeutic potential before human clinical work. With only two current positions publicly identified and no disclosed hiring program, revenue scale, regulatory approval, or commercial launch, EMHANCE remains in the technology-validation phase. Further grants, clinical evidence, and regulatory progress are likely to determine its next growth stage.